Eli Lilly and Company (LLY) Stock Analysis — Probabli.AI
AI-powered analysis for LLY (Eli Lilly and Company): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
← Healthcare Stocks
Last price: $895.17 · Market cap: $829.7B · AI outlook: Bullish
Eli Lilly demonstrates strong fundamentals, underscored by consistent earnings beats, a robust pipeline, and strategic market expansions. While recognizing potential risks, these strengths position it well for above-average growth.
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 30% · Bear 15%
- 1-year price estimates — P10: $750 / P50: $1,100 / P90: $1,300
- Eli Lilly is strategically positioned with a robust pipeline and expanding markets, complemented by strong fundamentals, as evidenced by recent earnings growth and consistent outperformance against estimates.
5-Year Outlook
- Bull 60% · Neutral 25% · Bear 15%
- 5-year price estimates — P10: $1,000 / P50: $1,600 / P90: $2,200
SWOT Highlights
- Strength: Innovative drug pipeline.
- Strength: Consistently beats EPS estimates.
- Risk: Low dividend yield.
- Risk: High dependence on specific products.
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
19 Wall Street analysts rate LLY a BUY with a mean price target of $1,217.79. Eli Lilly and Company currently pays a dividend with a yield of approximately 0.77%.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
LLY forecast details · LLY sentiment details · LLY insider activity
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.